Ibogaine is a transformative psychedelic medicine that not only alters perception and mood, but also stops addictive behaviors. Ibogaine has a very long history of botanical use and in high doses as a sacrament in African rituals. In the 1960s, American a self-help groups provided public testimonials that a single dose of ibogaine alleviated drug craving, opioid withdrawal symptoms and prevented relapse for weeks, months and sometimes years. Online forums endorse the benefits of ibogaine as an “addiction interrupter” and present-day estimates suggest that more than ten thousand people have sought treatment with ibogaine in unregulated countries. Ibogaine, granted regulatory approval for human testing in a Phase 1/2a clinical trial, joins the current landscape of psychedelic medicines in clinical development.